Active Not Recruiting PHASE1 INTERVENTIONAL 5-arm NCT06337643

A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine

A Phase 1, First-in Human, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of the Tolerability, Safety, and Immunogenicity of MVX01, a Pneumococcal Vaccine Candidate, in Healthy Adult Participants

Sponsor: Matrivax Research and Development Corporation

Conditions Pneumococcal Vaccine

Interventions MVX01 MVX01 Placebo

Updated 3 times since 2024 Last updated: Mar 22, 2024 Started: Mar 7, 2023 Primary completion: Apr 16, 2024 Completion: Apr 16, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06337643, this PHASE1 trial focuses on Pneumococcal Vaccine and remains ongoing. Sponsored by Matrivax Research and Development Corporation, it has been updated 3 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Active Not Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1
Apr 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE1

First recorded

Mar 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Matrivax Research and Development Corporation

Data source: Matrivax Research and Development Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Knoxville, United States
• Savannah, United States